

George J Bosl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6148524/publications.pdf>

Version: 2024-02-01

173
papers

11,336
citations

20817

60
h-index

30922

102
g-index

175
all docs

175
docs citations

175
times ranked

5984
citing authors

#	ARTICLE	IF	CITATIONS
1	Testicular Germ-Cell Cancer. New England Journal of Medicine, 1997, 337, 242-254.	27.0	832
2	TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. Journal of Urology, 1998, 159, 133-138.	0.4	384
3	Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. Journal of Clinical Oncology, 2005, 23, 6549-6555.	1.6	353
4	Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. Journal of Clinical Oncology, 2007, 25, 247-256.	1.6	326
5	Medical Treatment of Advanced Testicular Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 672.	7.4	307
6	Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors. Cancer Research, 2006, 66, 820-827.	0.9	275
7	Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up. Journal of Clinical Oncology, 2012, 30, 3752-3763.	1.6	243
8	Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. Journal of Clinical Oncology, 2000, 18, 2413-2418.	1.6	228
9	Teratoma with malignant transformation in germ cell tumors in men. Cancer, 1985, 56, 860-863.	4.1	225
10	Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer, 1985, 55, 527-534.	4.1	217
11	Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion. Journal of Urology, 1988, 139, 470-474.	0.4	211
12	Chemotherapy for Teratoma With Malignant Transformation. Journal of Clinical Oncology, 2003, 21, 4285-4291.	1.6	211
13	TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. Journal of Clinical Oncology, 2010, 28, 1706-1713.	1.6	192
14	Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. Journal of Clinical Oncology, 2000, 18, 1173-1180.	1.6	187
15	Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. Journal of Clinical Oncology, 2005, 23, 2781-2788.	1.6	185
16	CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity. Radiology, 2011, 258, 41-56.	7.3	180
17	Surgery for a Post-Chemotherapy Residual Mass in Seminoma. Journal of Urology, 1997, 157, 860-862.	0.4	157
18	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene, 1998, 16, 2345-2349.	5.9	148

#	ARTICLE	IF	CITATIONS
19	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 4000-4007.	1.6	147
20	Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes and Cancer, 1993, 8, 230-236.	2.8	141
21	CLINICAL STAGE I TESTIS CANCER: LONG-TERM OUTCOME OF PATIENTS ON SURVEILLANCE. Journal of Urology, 1998, 159, 855-858.	0.4	137
22	Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. Journal of Clinical Oncology, 2007, 25, 4365-4369.	1.6	132
23	Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). Cancer, 1991, 67, 1305-1310.	4.1	127
24	Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Molecular Cancer, 2004, 3, 16.	19.2	125
25	The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer, 1990, 66, 2476-2481.	4.1	119
26	Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. Journal of Clinical Oncology, 2007, 26, 85-90.	1.6	119
27	Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. Journal of Clinical Oncology, 2007, 25, 5597-5602.	1.6	114
28	Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. Journal of the National Cancer Institute, 1993, 85, 60-62.	6.3	112
29	Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes and Cancer, 1989, 1, 83-87.	2.8	109
30	Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. Journal of Clinical Oncology, 2008, 26, 5524-5529.	1.6	107
31	High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer, 1992, 69, 550-556.	4.1	105
32	Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer, 1994, 74, 1329-1334.	4.1	105
33	RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. Journal of Urology, 2005, 174, 557-560.	0.4	103
34	Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head and Neck, 1996, 18, 405-411.	2.0	100
35	Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. Journal of Clinical Oncology, 2001, 19, 682-688.	1.6	99
36	Characteristic promoter hypermethylation signatures in male germ cell tumors. Molecular Cancer, 2002, 1, 8.	19.2	99

#	ARTICLE	IF	CITATIONS
37	Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037.	1.6	99
38	Extragenital and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. <i>Cancer</i> , 1991, 67, 2049-2057.	4.1	97
39	Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943.	0.4	97
40	Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025.	1.6	95
41	Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608.	1.6	92
42	Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294.	1.6	91
43	Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467.	1.6	90
44	Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357.	4.1	88
45	Presence of Somatic Mutations within <i>PIK3CA</i> , <i>AKT</i> , <i>RAS</i> , and <i>FGFR3</i> but not <i>BRAF</i> in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720.	7.0	88
46	Amplification of the 3q26.3 Locus Is Associated with Progression to Invasive Cancer and Is a Negative Prognostic Factor in Head and Neck Squamous Cell Carcinomas. <i>American Journal of Pathology</i> , 2002, 161, 365-371.	3.8	86
47	Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003, 62, 732-736.	1.0	86
48	Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , 2009, 22, 1066-1074.	5.5	85
49	Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. <i>International Journal of Surgical Pathology</i> , 2002, 10, 23-32.	0.8	84
50	Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. <i>Cancer</i> , 1986, 57, 978-983.	4.1	81
51	Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. <i>PLoS ONE</i> , 2012, 7, e51563.	2.5	78
52	Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6999-7004.	1.6	77
53	Biology and Genetics of Adult Male Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5512-5518.	1.6	73
54	Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , 2007, 109, 528-535.	4.1	73

#	ARTICLE	IF	CITATIONS
55	The Management of Patients with Nonseminomatous Germ Cell Tumors of the Testis with Serologic Disease Only After Orchiectomy. <i>Journal of Urology</i> , 1994, 152, 111-113.	0.4	71
56	Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , 1994, 73, 2520-2526.	4.1	70
57	Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2006, 176, 100-104.	0.4	70
58	Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247.	1.6	70
59	Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.	2.6	66
60	Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma?. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 122-127.	2.8	62
61	Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent. <i>Journal of Clinical Oncology</i> , 2002, 20, 2980-2987.	1.6	61
62	Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , 2005, 24, 5101-5107.	5.9	57
63	Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 703-708.	0.8	56
64	Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162.	0.4	56
65	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528.	1.6	56
66	Tumor markers in advanced nonseminomatous testicular cancer. <i>Cancer</i> , 1981, 47, 572-576.	4.1	55
67	Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , 1981, 47, 328-332.	4.1	54
68	Larynx Preservation with Combined Chemotherapy and Radiation Therapy in Advanced Hypopharynx Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 1994, 111, 31-37.	1.9	54
69	Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.	4.1	50
70	Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.	0.4	49
71	The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435.	1.0	47
72	Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 21-29.	2.8	46

#	ARTICLE	IF	CITATIONS
73	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411.	7.0	44
74	A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. , 1998, 20, 497-503.		43
75	Does Size Matter? Association Between Number of Patients Treated and Patient Outcome in Metastatic Testicular Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 816-818.	6.3	42
76	Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241.	1.1	42
77	Two-drug therapy in patients with metastatic germ cell tumors. <i>Cancer</i> , 1991, 67, 28-32.	4.1	41
78	Tumor classification and size in germ-cell testicular cancer. Influence on the occurrence of metastases. <i>Cancer</i> , 1982, 50, 1591-1595.	4.1	40
79	Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470.	4.1	37
80	RECOGNIZING ABNORMAL MARKER RESULTS THAT DO NOT REFLECT DISEASE IN PATIENTS WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 2000, 163, 796-801.	0.4	37
81	Physical Mapping of a Commonly Deleted Region, the Site of a Candidate Tumor Suppressor Gene, at 12q22 in Human Male Germ Cell Tumors. <i>Genomics</i> , 1996, 35, 562-570.	2.9	36
82	Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2221-2225.	1.6	35
83	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	1.4	34
84	Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852.	4.1	33
85	Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997.	2.5	33
86	Decompression of epidural metastases from germ cell tumors with chemotherapy. <i>Journal of Neuro-Oncology</i> , 1990, 8, 275-80.	2.9	32
87	Double-Blind, Placebo-Controlled, Randomized Trial of Granulocyte-Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0.784314 rg32 /Overl	1.4	32
88	Interrogation of a Context-Specific Transcription Factor Network Identifies Novel Regulators of Pluripotency. <i>Stem Cells</i> , 2015, 33, 367-377.	3.2	32
89	VP-16 and cisplatin in the treatment of patients with refractory germ cell tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 327-330.	1.3	31
90	Sarcoidosis, a sarcoid-like lymphadenopathy, and testicular germ cell tumors. <i>American Journal of Medicine</i> , 1990, 89, 651-656.	1.5	31

#	ARTICLE	IF	CITATIONS
91	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767.	5.9	31
92	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	1.6	31
93	all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686.	4.1	30
94	Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.	4.1	30
95	Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096.	1.0	29
96	Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165.	2.6	28
97	Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.	1.0	28
98	Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769.	1.9	28
99	Molecular events in germ cell tumours: linking chromosome 12 gain, acquisition of pluripotency and response to cisplatin. <i>BJU International</i> , 2009, 104, 1334-1338.	2.5	27
100	Optimal Management of Clinical Stage I Testis Cancer: One Size Does Not Fit All. <i>Journal of Clinical Oncology</i> , 2013, 31, 3477-3479.	1.6	27
101	Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317.	4.1	26
102	Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688.	1.6	25
103	Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.	4.1	25
104	Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158.	0.4	24
105	Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. <i>Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , 2002, 13, 257-64.	0.8	24
106	Carboplatin in Clinical Stage I Seminoma: Too Much and Too Little at the Same Time. <i>Journal of Clinical Oncology</i> , 2011, 29, 949-952.	1.6	23
107	The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.	4.1	22
108	A 3-Mb High-Resolution BAC/PAC Contig of 12q22 Encompassing the 830-kb Consensus Minimal Deletion in Male Germ Cell Tumors. <i>Genome Research</i> , 1999, 9, 662-671.	5.5	22

#	ARTICLE	IF	CITATIONS
109	Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. <i>Urology</i> , 1983, 21, 559-561.	1.0	21
110	Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. <i>Cancer</i> , 1991, 67, 1299-1304.	4.1	21
111	Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.	2.6	21
112	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. <i>American Journal of Human Genetics</i> , 2012, 91, 379-383.	6.2	21
113	Primary Retroperitoneal Lymph Node Dissection in Low-stage Testicular Germ Cell Tumors: A Detailed Pathologic Study With Clinical Outcome Analysis With Special Emphasis on Patients Who Did Not Receive Adjuvant Therapy. <i>Urology</i> , 2013, 82, 1341-1347.	1.0	21
114	Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. <i>Functional and Integrative Genomics</i> , 2005, 5, 59-69.	3.5	20
115	Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.	0.4	20
116	Carboplatin for Stage I Seminoma and the Sword of Damocles. <i>Journal of Clinical Oncology</i> , 2005, 23, 8566-8569.	1.6	19
117	Time to publication of oncology trials and why some trials are never published. <i>PLoS ONE</i> , 2017, 12, e0184025.	2.5	19
118	Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. <i>Cancer</i> , 1983, 51, 2121-2125.	4.1	18
119	Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846.	2.5	18
120	Malignant carcinoid of the gallbladder: Third reported case and review of the literature. <i>Journal of Surgical Oncology</i> , 1980, 13, 215-222.	1.7	17
121	Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.	1.6	17
122	A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576.	2.2	16
123	Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364.	1.0	16
124	ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116.	1.8	16
125	miR-18b and miR-518b Target <i>FOXN1</i> During Epithelial Lineage Differentiation in Pluripotent Cells. <i>Stem Cells and Development</i> , 2014, 23, 1149-1156.	2.1	15
126	Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in "Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , 2018, 36, 837-840.	1.6	15

#	ARTICLE	IF	CITATIONS
127	Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521.	1.6	14
128	Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.	1.0	14
129	Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330.	2.6	13
130	High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering experience (1988-1999). , 1999, 83, 834-838.		12
131	Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179.	2.6	12
132	Constitutive Gene Expression Predisposes Morphogen-Mediated Cell Fate Responses of NT2/D1 and 27X-1 Human Embryonal Carcinoma Cells. <i>Stem Cells</i> , 2007, 25, 771-778.	3.2	12
133	Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.	1.0	12
134	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.	1.0	12
135	Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.	1.6	11
136	Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.	1.0	10
137	Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. <i>Cancer</i> , 2011, 117, 1911-1916.	4.1	10
138	Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.	0.4	10
139	Germ cell tumor clinical trials in North America. , 1999, 17, 257-262.		9
140	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320.	3.0	9
141	830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277.	0.4	9
142	Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107.	4.2	9
143	Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267.	2.6	8
144	Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. <i>BJU International</i> , 2012, 110, 950-955.	2.5	8

#	ARTICLE	IF	CITATIONS
145	Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification. Stem Cell Reports, 2016, 6, 772-783.	4.8	8
146	Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. Oncologist, 2021, 26, 483-491.	3.7	8
147	Treatment of stage I seminoma: is it time to change your practice?. Journal of Hematology and Oncology, 2008, 1, 22.	17.0	7
148	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology, 2018, 118, 114-118.	1.0	7
149	Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. European Urology, 2019, 76, 612-614.	1.9	7
150	Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. Biology of Blood and Marrow Transplantation, 2008, 14, 595-600.	2.0	6
151	Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. Urology, 2016, 95, 128-131.	1.0	6
152	Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. Urology, 2019, 124, 174-178.	1.0	6
153	Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. Urology, 2012, 79, 1079-1084.	1.0	5
154	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical Genitourinary Cancer, 2015, 13, 453-460.	1.9	5
155	Status and prospects of the treatment of disseminated germ-cell tumors. World Journal of Urology, 1984, 2, 38-42.	2.2	4
156	The future of therapy for nonseminomatous germ cell tumors. Chest Surgery Clinics of North America, 2002, 12, 769-789.	0.7	4
157	Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. Annals of Thoracic Surgery, 2021, 111, 1141-1149.	1.3	4
158	Surgery of Testicular Tumors. , 2012, , 871-892.e6.		4
159	Abnormal colony formation and prostaglandin e responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy. Cancer, 1987, 60, 312-317.	4.1	3
160	Expression of ID Genes in Differentiated Elements of Human Male Germ Cell Tumors. Diagnostic Molecular Pathology, 2001, 10, 248-254.	2.1	3
161	The Current Status of Salvage Chemotherapy for Patients with Cisplatin-Resistant Germ Cell Tumors. Cancer Investigation, 1993, 11, 94-96.	1.3	2
162	Recurrent Germ Cell Tumors: Let's Try to Cure Them All. Journal of Oncology Practice, 2016, 12, 445-447.	2.5	2

#	ARTICLE	IF	CITATIONS
163	Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. Journal of Clinical Oncology, 2006, 24, 5479-5481.	1.6	1
164	Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2010, 28, e740-e740.	1.6	1
165	Testicular granulosa cell tumors: rare tumors need to be studied too. Oncology, 2009, 23, 796.	0.5	1
166	Genetics and Biology of Adult Male Germ Cell Tumors. , 2005, , 221-229.		0
167	Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nature Clinical Practice Oncology, 2007, 4, 508-509.	4.3	0
168	Reply to S. Stenning et al and J. Lipshitz. Journal of Clinical Oncology, 2011, 29, 4211-4212.	1.6	0
169	Reply. Urology, 2013, 82, 1346-1347.	1.0	0
170	Germ Cell Tumors: Looking to the Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e253-e258.	3.8	0
171	Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2020, 38, 3074-3075.	1.6	0
172	Germ Cell Tumors. , 2002, , 287-296.		0
173	Advances in the Understanding of Germ Cell Tumour Biology. , 2002, , 23-29.		0